Nefecon and Ambrisentan in IgA Nephropathy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 129 participants.
Also called NCT07030894
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 129 participants
- Registry
-
NCT07030894
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07030894. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Nefecon and Ambrisentan in IgA Nephropathy
- Acronym
- BAIN
- Condition
- IgA Nephropathy
- Condition
- Chronic Kidney Disease
- Condition
- Proteinuria
- Intervention (Drug)
- "Nefecon®","Ambrisentan"
- Lead sponsor
- The First Hospital of Jilin University
Record details
- Record id
cardio:ct-nct07030894- Content hash
1342a128c12f851f10d43223ea4aa3018dce35a6b22ab8bc2826c177d8d01916